(0.36%) 5 118.32 points
(0.31%) 38 360 points
(0.36%) 15 986 points
(-1.11%) $82.92
(3.43%) $1.989
(0.02%) $2 347.70
(0.14%) $27.57
(3.14%) $951.05
(-0.05%) $0.934
(-0.05%) $11.02
(-0.31%) $0.798
(1.84%) $93.57
Live Chart Being Loaded With Signals
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 700.00 |
Vidutinė apimtis | 9 848.00 |
Rinkos kapitalizacija | 148.43M |
EPS | $-0.170 ( 2024-03-14 ) |
Kita pelno data | ( $-0.250 ) 2024-05-08 |
Last Dividend | $0.0500 ( 2023-04-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.97 |
ATR14 | $0 (0.00%) |
HLS THERAPEUTICS INC Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
HLS THERAPEUTICS INC Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $63.07M |
Bruto pelnas: | $55.45M (87.91 %) |
EPS: | $-0.850 |
FY | 2023 |
Pajamos: | $63.07M |
Bruto pelnas: | $55.45M (87.91 %) |
EPS: | $-0.850 |
FY | 2022 |
Pajamos: | $61.47M |
Bruto pelnas: | $56.49M (91.90 %) |
EPS: | $-0.730 |
FY | 2021 |
Pajamos: | $60.01M |
Bruto pelnas: | $56.04M (93.38 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
HLS THERAPEUTICS INC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0500 | 2019-01-30 |
Last Dividend | $0.0500 | 2023-04-27 |
Next Dividend | $0 | N/A |
Payout Date | 2023-06-15 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $0.900 | -- |
Avg. Dividend % Per Year | 0.75% | -- |
Score | 2.66 | -- |
Div. Sustainability Score | 3.14 | |
Div.Growth Potential Score | 1.423 | |
Div. Directional Score | 2.28 | -- |
Year | Amount | Yield |
---|---|---|
2019 | $0.200 | 1.43% |
2020 | $0.200 | 0.81% |
2021 | $0.200 | 1.18% |
2022 | $0.200 | 1.36% |
2023 | $0.100 | 0.99% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
XML.TO | Dividend Junior | 2023-06-26 | Annually | 9 | 1.17% | |
QDX.TO | Dividend Knight | 2023-09-18 | Quarterly | 7 | 1.53% | |
FRU.TO | Dividend Royal | 2023-09-28 | Monthly | 22 | 4.44% | |
AFN.TO | Dividend King | 2023-09-28 | Quarterly | 19 | 0.99% | |
VCN.TO | Dividend Junior | 2023-06-30 | Quarterly | 12 | 1.60% | |
MRU.TO | Dividend King | 2023-08-29 | Quarterly | 30 | 0.99% | |
DCU.TO | Dividend Knight | 2023-09-21 | Monthly | 8 | 1.68% | |
XUU.TO | Dividend Junior | 2023-09-25 | Quarterly | 10 | 0.78% | |
RUS.TO | Dividend King | 2023-08-28 | Quarterly | 25 | 3.35% | |
HBAL.TO | No Dividend Player | 2023-08-30 | Annually | 6 | 0.08% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.436 | 1.500 | -8.73 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.132 | 1.200 | -4.39 | -5.27 | [0 - 0.3] |
returnOnEquityTTM | -0.256 | 1.500 | -3.96 | -5.94 | [0.1 - 1] |
payoutRatioTTM | -0.0871 | -1.000 | -0.871 | 0.871 | [0 - 1] |
currentRatioTTM | 1.652 | 0.800 | 6.74 | 5.39 | [1 - 3] |
quickRatioTTM | 1.223 | 0.800 | 7.51 | 6.01 | [0.8 - 2.5] |
cashRatioTTM | 0.823 | 1.500 | 6.54 | 9.81 | [0.2 - 2] |
debtRatioTTM | 0.419 | -1.500 | 3.01 | -4.52 | [0 - 0.6] |
interestCoverageTTM | -1.143 | 1.000 | -1.534 | -1.534 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.501 | 2.00 | 9.83 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.499 | 2.00 | 9.75 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.897 | -1.500 | 6.41 | -9.62 | [0 - 2.5] |
grossProfitMarginTTM | 0.879 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.159 | 1.000 | -5.17 | -5.17 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.180 | 1.000 | -0.110 | -0.110 | [0.2 - 2] |
assetTurnoverTTM | 0.302 | 0.800 | -1.322 | -1.058 | [0.5 - 2] |
Total Score | 3.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.90 | 1.000 | -0.495 | 0 | [1 - 100] |
returnOnEquityTTM | -0.256 | 2.50 | -2.54 | -5.94 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.499 | 2.00 | 9.83 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.501 | 2.00 | 9.83 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.0871 | 1.500 | -0.871 | 0.871 | [0 - 1] |
pegRatioTTM | 0.115 | 1.500 | -2.56 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.250 | 1.000 | 6.24 | 0 | [0.1 - 0.5] |
Total Score | 1.423 |
HLS THERAPEUTICS INC
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.